NasdaqGS:PTCTBiotechs
Assessing PTC Therapeutics (PTCT) Valuation After Health Canada’s Sephience Approval Expands PKU Market Potential
PTC Therapeutics (PTCT) just secured Health Canada approval for Sephience, extending its phenylketonuria treatment to a wide range of Canadian patients and building on earlier US and European green lights.
See our latest analysis for PTC Therapeutics.
The Sephience approval lands as momentum in PTC Therapeutics' shares has been building, with a roughly 30 percent 3 month share price return and about 70 percent 1 year total shareholder return. This underscores how regulatory wins are reshaping...